Know Cancer

or
forgot password

Evaluation of the Radionics Body Localizer System and XPLAN/IMRT for Extra-Cranial Sites: A Pilot Study


N/A
N/A
N/A
Not Enrolling
Both
Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

Evaluation of the Radionics Body Localizer System and XPLAN/IMRT for Extra-Cranial Sites: A Pilot Study


OBJECTIVES:

- Determine the ability of the Radionics Body System™ to immobilize and re-localize
patients receiving radiotherapy to extra-cranial sites of cancer.

- Determine the accuracy of radiation dose calculations for extra-cranial sites of cancer
when using the XPLAN™-intensity modulated radiation therapy (XPLAN™/IMRT) integrated
software in this system.

OUTLINE: Patients receiving radiotherapy have a Body Localizer cast constructed and undergo
a CT scan while immobilized in the Body Localizer. Patients undergo another CT scan in the
treatment position using the standard alpha cradle. The XPLAN™-intensity modulated radiation
therapy (XPLAN™/IMRT)-generated treatment plan is compared to the standard treatment plan to
verify that the calculated dose is within 2-3 percent of the planned dose using standard
technique. Patients undergo sets of CT scans 3 additional times over the next few weeks for
a total of 8 CT scans Patients may undergo additional CT scans before and after radiotherapy
treatments for a maximum of 5 CT scans per week performed over the course of radiotherapy.

PROJECTED ACCRUAL: Approximately 60 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Cancer for which a course of radiotherapy to an extra-cranial site is required

- Head and neck sites excluded

- Initial treatment field (or cone down field) must be no greater than 12 X 10 cm

PATIENT CHARACTERISTICS:

Age

- Not specified

Performance status

- Not specified

Life expectancy

- Not specified

Hematopoietic

- Not specified

Hepatic

- Not specified

Renal

- Not specified

Cardiovascular

- No right heart insufficiency

Other

- Not pregnant or nursing

- Fertile patients must use effective contraception

- Weight must not exceed 150 kilograms (330 pounds)

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- Not specified

Endocrine therapy

- Not specified

Radiotherapy

- See Disease Characteristics

Surgery

- Not specified

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Principal Investigator

Steven Seigenberg, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Fox Chase Cancer Center

Authority:

United States: Federal Government

Study ID:

CDR0000304713

NCT ID:

NCT00436397

Start Date:

June 2002

Completion Date:

August 2005

Related Keywords:

  • Unspecified Adult Solid Tumor, Protocol Specific
  • unspecified adult solid tumor, protocol specific

Name

Location

Fox Chase Cancer Center - PhiladelphiaPhiladelphia, Pennsylvania  19111-2497